Harbour BioMed

Harbour BioMed signs $350m anti-PD-L1 deal with Kelun-Biotech

Chinese companies Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical have entered into an exclusive strategic collaboration for the development and commercialisation…

Glenmark partners Harbour BioMed to develop oncology candidate in China

Glenmark Pharmaceuticals has signed an exclusive licence agreement with Harbour BioMed for the development, manufacture and commercialisation of its immuno-oncology…